| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Sodium caprate's primary mechanism of action is as a penetration enhancer. It increases the permeability of biological membranes by interacting with membrane lipids and tight junctions. It has also been shown to have anticancer effects on gastric cancer cells, inducing apoptosis and necrosis. It is a metabolite and has amphiphilic character.
|
|---|---|
| ln Vitro |
In study pertaining to life sciences, sodium decanoate is a biochemical reagent that can be utilized as an organic substance or biological material.
In vitro, Sodium caprate increases permeation clearance and decreases electric membrane resistance in colonic membranes. It induces apoptosis and necrosis in a concentration-dependent manner in human gastric cancer cells. These effects demonstrate its potential as both a drug absorption enhancer and an anticancer agent. |
| ln Vivo |
In vivo, Sodium caprate has been shown to increase drug absorption and bioavailability across biological membranes. Its effects have been studied in rat and human colons, showing that the rat colon can be used as a model for human colon for studies of enhancer effects. Its potential anticancer effects have also been investigated.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not typically performed for Sodium caprate, as it functions primarily as a penetration enhancer rather than a receptor ligand. Its activity is assessed by measuring its effects on membrane permeability and electrical resistance in tissue models.
|
| Cell Assay |
In vitro cell-based assays for Sodium caprate involve treating cells, such as gastric cancer cells, with the compound to assess its effects on cell viability and apoptosis. Its ability to induce apoptosis and necrosis is measured using standard cell death assays. Its effects on membrane permeability are often studied using epithelial cell monolayers.
|
| Animal Protocol |
In vivo animal experiments for Sodium caprate have been conducted in rat models to study its effects on drug absorption. It is typically co-administered with drugs, and its effect on the bioavailability of the co-administered drug is measured. Its effects on colonic permeability have also been studied in rats.
|
| ADME/Pharmacokinetics |
Sodium caprate is a sodium salt of capric acid and is easily soluble in water. It is used as a penetration enhancer in pharmaceutical formulations. Its pharmacokinetic properties are related to its function as a fatty acid salt, and it is typically absorbed and metabolized like other medium-chain fatty acids.
|
| Toxicity/Toxicokinetics |
Sodium caprate is generally recognized as safe (GRAS) for use as a food additive and pharmaceutical excipient. Its toxicity is low at typical concentrations used for drug absorption enhancement. However, high concentrations may cause local irritation or toxicity. Its potential anticancer effects are being investigated.
|
| Additional Infomation |
Sodium caprate is a sodium salt of capric acid used primarily as a penetration enhancer to improve drug absorption. It also has potential anticancer effects on gastric cancer cells. It is a common pharmaceutical excipient and is generally recognized as safe.
|
| Molecular Formula |
C10H19NAO2
|
|---|---|
| Molecular Weight |
194.25
|
| Exact Mass |
194.128
|
| CAS # |
1002-62-6
|
| Related CAS # |
Decanoic acid-d19 sodium;1086096-26-5
|
| PubChem CID |
4457968
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
269.6ºC at 760 mmHg
|
| Melting Point |
~240 °C (dec.)
|
| Flash Point |
121.8ºC
|
| Vapour Pressure |
0.00355mmHg at 25°C
|
| LogP |
1.877
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
13
|
| Complexity |
116
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[Na+].[O-]C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
FIWQZURFGYXCEO-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/C10H20O2.Na/c1-2-3-4-5-6-7-8-9-10(11)12;/h2-9H2,1H3,(H,11,12);/q;+1/p-1
|
| Chemical Name |
sodium;decanoate
|
| Synonyms |
Caprinic acid sodium salt; Capric acid, sodium salt; Sodium caprate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~514.80 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.1480 mL | 25.7400 mL | 51.4801 mL | |
| 5 mM | 1.0296 mL | 5.1480 mL | 10.2960 mL | |
| 10 mM | 0.5148 mL | 2.5740 mL | 5.1480 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
